KR101060971B1 - 안트라닐산 유도체 수화물의 제조 방법 - Google Patents

안트라닐산 유도체 수화물의 제조 방법 Download PDF

Info

Publication number
KR101060971B1
KR101060971B1 KR1020047018344A KR20047018344A KR101060971B1 KR 101060971 B1 KR101060971 B1 KR 101060971B1 KR 1020047018344 A KR1020047018344 A KR 1020047018344A KR 20047018344 A KR20047018344 A KR 20047018344A KR 101060971 B1 KR101060971 B1 KR 101060971B1
Authority
KR
South Korea
Prior art keywords
hydrate
quinoline
formula
acid
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047018344A
Other languages
English (en)
Korean (ko)
Other versions
KR20050009706A (ko
Inventor
헤이맨데이비드프랭크
라이트마이클
Original Assignee
제노바 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제노바 리미티드 filed Critical 제노바 리미티드
Publication of KR20050009706A publication Critical patent/KR20050009706A/ko
Application granted granted Critical
Publication of KR101060971B1 publication Critical patent/KR101060971B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020047018344A 2002-05-14 2003-05-13 안트라닐산 유도체 수화물의 제조 방법 Expired - Fee Related KR101060971B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37975902P 2002-05-14 2002-05-14
US60/379,759 2002-05-14
PCT/GB2003/002060 WO2003095447A1 (en) 2002-05-14 2003-05-13 Process for the preparation of a hydrate of an anthranilic acid derivative

Publications (2)

Publication Number Publication Date
KR20050009706A KR20050009706A (ko) 2005-01-25
KR101060971B1 true KR101060971B1 (ko) 2011-09-01

Family

ID=29420557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047018344A Expired - Fee Related KR101060971B1 (ko) 2002-05-14 2003-05-13 안트라닐산 유도체 수화물의 제조 방법

Country Status (11)

Country Link
US (1) US7524861B2 (https=)
EP (1) EP1506188B1 (https=)
JP (1) JP4464814B2 (https=)
KR (1) KR101060971B1 (https=)
CN (1) CN100349888C (https=)
AT (1) ATE423778T1 (https=)
AU (1) AU2003233899B2 (https=)
BR (1) BR0309990A (https=)
CA (1) CA2485430C (https=)
DE (1) DE60326341D1 (https=)
WO (1) WO2003095447A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
PE20160605A1 (es) 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN104434947B (zh) * 2014-11-07 2016-11-09 滨州医学院附属医院 一种抗胆管癌的药物组合物及其应用
EP3378858A1 (en) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
AU2021358977A1 (en) * 2020-10-07 2023-04-27 Health Hope Pharma Hk Limited Acetamido-phenylbenzamide derivatives and methods of using the same
CN112724124A (zh) * 2021-01-18 2021-04-30 林剑雄 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用
CN117304105A (zh) * 2023-08-18 2023-12-29 中国科学院基础医学与肿瘤研究所(筹) 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100220538B1 (ko) * 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
CN100354265C (zh) * 1996-10-18 2007-12-12 埃克森诺瓦有限公司 邻氨基苯甲酸衍生物及其制备方法和作为多种抗性调节剂的用途
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
KR20050009706A (ko) 2005-01-25
AU2003233899A1 (en) 2003-11-11
CA2485430A1 (en) 2003-11-20
JP2005538051A (ja) 2005-12-15
CA2485430C (en) 2011-12-06
CN100349888C (zh) 2007-11-21
DE60326341D1 (de) 2009-04-09
US20050222199A1 (en) 2005-10-06
US7524861B2 (en) 2009-04-28
WO2003095447A1 (en) 2003-11-20
EP1506188B1 (en) 2009-02-25
JP4464814B2 (ja) 2010-05-19
ATE423778T1 (de) 2009-03-15
BR0309990A (pt) 2005-02-22
CN1665806A (zh) 2005-09-07
EP1506188A1 (en) 2005-02-16
AU2003233899B2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
KR101060971B1 (ko) 안트라닐산 유도체 수화물의 제조 방법
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
CN114195788B (zh) 一类四环化合物及其用途
CN114907387B (zh) 嘧啶并吡咯类kras抑制剂及其制备方法与应用
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
WO2021218110A1 (zh) 一类苯并噻唑基联芳基类化合物、制备方法和用途
KR20060027802A (ko) ３환계 화합물
EA022341B1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CN1863795B (zh) P-糖蛋白抑制剂,其制备方法和包括该抑制剂的药物组合物
WO2003000660A1 (fr) Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
CN115867540A (zh) 硝羟喹啉衍生物及其制备方法和用途
CN114585621A (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用
WO2025124460A1 (zh) 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
RU2163599C2 (ru) Таксаны, способ их получения и лекарственный препарат на их основе
CN121013856A (zh) Egfr降解剂、其药物组合物及其用途
CN114616234B (zh) 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
CN109081818B (zh) 新型吲哚胺2,3-双加氧化酶抑制剂
KR20150105302A (ko) 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
CN112778154B (zh) 芳基烷基醚化合物及其衍生物，制备方法、药物组合物和应用
TWI918767B (zh) 含二并環類衍生物抑制劑自由鹼的晶型及其製備方法和應用
JP3153555B2 (ja) ファルネシルタンパク質トランスフェラーゼのインヒビターとして有用な新規三環式ｎ―シアノイミン
CN120192318A (zh) 吡咯里嗪并[2,3-c]喹啉衍生物、合成方法及其应用
HK40068190A (en) Imidazoquinoline amine derivatives, pharmaceutical compositions and use thereof
CN119241548A (zh) 含稠合苯环的二氢喋啶酮衍生物及其用途
HK40068190B (zh) 咪唑并喹啉胺衍生物、及其药物组合物和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140826

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140826